Kodiak Sciences Inc. Stock Price, News & Analysis

Kodiak Sciences (NASDAQ: KOD) reported Q2 2025 financial results and business updates, highlighting progress across its late-stage clinical pipeline. The company's three key assets - tarcocimab, KSI-501, and KSI-101 - are advancing with multiple Phase 3 readouts expected between 1Q 2026 and 1Q 2027.

Notable highlights include promising KSI-101 Phase 1b data in MESI patients, showing rapid anatomical improvements and >90% achieving dryness by week 8. Financially, Kodiak reported a net loss of $54.3 million ($1.03 per share) and ended Q2 with $104.2 million cash, expected to fund operations into 2026. R&D expenses increased to $42.8 million, while G&A expenses decreased to $12.8 million.

Kodiak Sciences (NASDAQ: KOD), a precommercial retina-focused biotechnology company, will host a virtual investor R&D Day on July 16, 2025, from 4:00 PM to 5:30 PM ET. The event will showcase the company's three late-phase clinical assets - tarcocimab, KSI-501, and KSI-101 - with presentations from senior leadership and industry experts.

The company's ABC Platform® uses molecular engineering to combine protein-based and chemistry-based therapies for treating retinal diseases. All three clinical assets are targeting Phase 3 topline data in 2026. The event will be accessible via webcast, with recording available 24 hours after the presentation.

Kodiak Sciences (NASDAQ:KOD) announced its participation in the 2025 Congress of the International Ocular Inflammation Society (IOIS) in Rio de Janeiro, where management and key opinion leaders will present highlights of KSI-101, their investigational treatment for macular edema secondary to inflammation (MESI).

KSI-101 is a first-in-class bispecific intravitreal biologic designed to simultaneously target both interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF). The presentation will address MESI pathophysiology, current treatment limitations, and clinical data for KSI-101. The breakfast symposium is scheduled for June 27, 2025, at 7:00 AM BRT.

Kodiak Sciences (NASDAQ: KOD), a biopharmaceutical company focused on developing treatments for retinal diseases, announced that CEO Victor Perlroth will present at the 2025 Jefferies Global Healthcare Conference. The presentation is scheduled for June 5, 2025, at 9:20am ET in New York City. Investors can access a live webcast of the presentation through Kodiak's investor relations website at ir.kodiak.com, where it will remain available for replay for a limited time after the event.

Kodiak Sciences (KOD) reported its Q1 2025 financial results and business updates. The company ended Q1 with $138.9 million in cash, expected to fund operations into 2026. The quarter saw a net loss of $57.5 million ($1.09 per share), compared to $43.0 million ($0.82 per share) in Q1 2024. R&D expenses increased to $43.6 million from $29.9 million year-over-year, while G&A expenses slightly decreased to $15.4 million.

The company is advancing as a precommercial stage retina-focused biotech with three Phase 3 assets targeting topline data in 2026. Kodiak plans to host an Investor R&D Update on July 16, 2025, featuring updates on their pipeline including Tarcocimab (GLOW2 and DAYBREAK studies), KSI-501, and KSI-101's APEX Phase 1b trial results.

Kodiak Sciences (KOD) will present seven scientific presentations at ARVO 2025, showcasing their ABC® (Antibody Biopolymer Conjugate) platform technology. Key highlights include: - Research on KSI-101 (in Phase 1b) and KSI-102 for ocular inflammatory diseases - New bispecific inhibitors for Geographic Atrophy (GA) treatment - Advancements in their ABCD platform for enhanced drug delivery The presentations focus on three main areas: 1. Ocular Inflammatory Disease - Including promising data on dual-targeting antibodies against TNF-α and IL-6 2. Geographic Atrophy - Novel approach combining complement regulators with anti-VEGF and anti-IL-6 antibodies 3. ABCD Platform Technology - Demonstrating high drug-antibody ratio (DAR) capabilities and improved therapeutic delivery Early clinical data shows KSI-101 effectively normalizes macular edema and improves vision in MESI patients across all dose levels.

Kodiak Sciences (KOD) has reported its Q4 and full year 2024 financial results, highlighting progress across its pipeline. The company ended Q4 2024 with $168.1 million in cash, expected to support operations into 2026. The Q4 net loss was $44.1 million ($0.84 per share), compared to $59.5 million in Q4 2023.

Key developments include two Phase 3 studies for tarcocimab: GLOW2 and DAYBREAK, with topline data expected in 1Q and 2Q 2026 respectively. The company plans to file a single BLA in 2026 for wet AMD, retinal vein occlusion, and diabetic retinopathy indications. KSI-501 is being evaluated in the DAYBREAK study, while KSI-101 received FDA Orphan Drug Designation and is progressing in the APEX Phase 1b trial.

R&D expenses decreased to $31.8 million in Q4 2024 from $46.6 million in Q4 2023, while G&A expenses reduced to $14.4 million from $16.7 million year-over-year.

Kodiak Sciences (KOD) has completed enrollment in its GLOW2 Phase 3 clinical trial of tarcocimab tedromer for diabetic retinopathy (DR). The study successfully randomized over 250 patients, surpassing the enrollment target. Topline clinical data is expected in Q1 2026, following the 48-week treatment duration.

The GLOW2 design mirrors the successful GLOW1 study, with an additional loading dose for provider flexibility. This represents Kodiak's second registrational study in DR. The company plans to file a single BLA for tarcocimab covering wet AMD, DR, and RVO after receiving DAYBREAK topline data in Q2 2026.

The treatment shows promise with only 4 doses required in Year 1 and bi-annual dosing thereafter, addressing the current challenge where less than 1% of DR patients receive treatment due to the high frequency of injections required with existing therapies.

Kodiak Sciences (Nasdaq: KOD) announced its participation at the Glaucoma 360 New Horizons Forum 2025 on February 7, 2025, in San Francisco, where they will present their pipeline program for glaucoma treatment. The company is developing a groundbreaking dual-acting therapy using their Antibody Biopolymer Conjugate Drug (ABCD) platform.

The innovative 'duet' therapy targets both neuroinflammation and elevated intraocular pressure in glaucoma treatment. It specifically targets the NLRP3 inflammasome while incorporating an IOP-lowering molecule, designed for quarterly dosing. This approach aims to address the underlying mechanism of optic nerve damage in glaucoma, which affects approximately 76 million people worldwide.

Dr. Dolly Chang, Chief Scientific Officer, will present 'Addressing Optic Neuropathy Through Neuroinflammation Modulation and IOP Lowering with the ABCD Platform: A Polymedicine Approach to Glaucoma' as part of the session 'Beyond IOP: Targeting Neuroprotection and Vision Restoration.'